Saturday 17 October 2026
Export ENSC’s income statement to Excel — free account
Ensysce Biosciences, Inc.
ENSC Healthcare Biotechnology
Ensysce Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.1 million, down 2.75% from fiscal 2024. In the quarter to June 2026, revenue fell 15.1%, EPS grew 74.7% and free cash flow grew 27.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.52
0.08
−13.33%
Follow ENSC
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | — | — | — | 3 | 3 | 5 | 3 |
Altman Z-Score |
— | — | — | (232.51) | (8.85) | (40.29) | (75.11) | (33.23) | (29.36) |
P/S ratio |
— | — | — | 0.00 | 26.83 | 0.68 | 1.13 | 1.09 | 0.46 |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | (674.59) | (25.86) | (94.18) | (175.66) | (78.25) | (67.34) |
Beneish M-Score |
— | — | — | — | — | (7.88) | (2.77) | (1.78) | (1.90) |
P/Operating CF |
— | — | — | (369.00) | (25.15) | (0.52) | (1.40) | (7.44) | (1.54) |
P/B ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 1.68 | 0.82 |
Price to Tangible BV |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 1.68 | 0.82 |
EV/Sales |
— | — | — | 0.00 | 24.81 | (0.24) | 0.99 | 0.57 | (0.23) |
EV/EBITDA |
— | — | — | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.11 |
EV/Operating CF |
— | — | — | (158.93) | (10.63) | 0.03 | (0.20) | (0.40) | 0.15 |
EV/FCF |
— | — | — | (158.93) | (10.63) | 0.03 | (0.20) | (0.40) | 0.15 |
Quick Ratio |
13.38 | 4.18 | 0.43 | 0.03 | 0.77 | 0.36 | 0.37 | 1.64 | 1.04 |
Current Ratio |
14.77 | 4.38 | 0.43 | 0.05 | 0.95 | 0.56 | 0.69 | 2.42 | 1.59 |
Net Debt/EBITDA |
14.25 | 1.73 | 0.15 | (0.79) | 0.39 | 0.12 | 0.11 | 0.63 | 0.42 |
Debt/Assets |
0.00% | 0.00% | 0.29% | 415.46% | 27.05% | 2.38% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.11 | (0.22) | (0.54) | (0.03) | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.04 | 0.42 | 0.23 | 0.52 | 1.25 | 0.78 |
Operating CF/Net income |
8.07 | (0.58) | 1.34 | (21.96) | 0.28 | 0.71 | 1.01 | 0.94 | 0.77 |
Capex/Depreciation |
— | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | (19.02) |
Interest Coverage |
— | (0.26) | (0.78) | (1.62) | (15.34) | (221.21) | (30.29) | (5.22) | (544.73) |
| (0.62%) | 42.44% | (21.35%) | (6.85%) | 403.43% | 411.65% | 454.02% | (585.44%) | (324.86%) | |
| (0.02%) | 1.04% | (0.53%) | 0.06% | (356.45%) | (224.96%) | (247.31%) | (192.34%) | (155.95%) | |
ROIC |
0.00% | (17.94%) | (46.18%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(1.45%) | 143.56% | 67.92% | (0.85%) | 3,648.75% | 602.29% | 1,017.72% | (254.57%) | (363.56%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 45.66 | 40.04 | 15.97 | 8.69 | 30.28 |
Research and Development Expense of Revenue |
— | — | — | 111.66% | 132.82% | 786.08% | 340.17% | 138.57% | 204.81% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 29.38% | 529.89% | 273.82% | 240.36% | 90.61% | 97.32% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | — | 4.55% | 3.45% | 42.47% | 39.42% | 2.12% | 3.50% |
Graham Net Nets |
— | — | — | (0.03) | (0.09) | (2.67) | (0.43) | 0.55 | 1.14 |
Graham Number |
— | — | — | 1,118.22 | 12,277.64 | 4,147.55 | 85.80 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | (0.08%) | (27.18%) | (1,581.09%) | (455.63%) | (164.56%) | (458.70%) |
Free Cash Flow Yield |
— | — | — | (0.63%) | (8.70%) | (1,035.15%) | (428.77%) | (132.05%) | (331.84%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 893.45 | 630.57 | 210.28 | 14.77 | 7.46 | 1.98 |
Operating CF per Share |
(0.20) | (728.41) | (838.12) | (283.48) | (1,471.82) | (1,490.62) | (71.39) | (10.75) | (3.05) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.05) |
Free Cash Flow per Share |
(0.20) | (728.41) | (838.12) | (283.48) | (1,471.82) | (1,490.62) | (71.39) | (10.75) | (3.10) |
Cash per Share |
1.66 | 975.53 | 624.24 | 44.14 | 2,190.13 | 262.31 | 7.44 | 5.02 | 1.69 |
Shareholders Equity per Share |
3.97 | 2,941.18 | 2,941.18 | (1,513.27) | (1,456.80) | (335.81) | (4.31) | 4.84 | 1.13 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.97 | 2,941.18 | 2,941.18 | (1,513.27) | (1,456.80) | (335.81) | (4.31) | 4.84 | 1.13 |
Free Cash Flow |
(0.25) | (1.24) | (1.42) | (1.25) | (8.24) | (17.89) | (10.78) | (7.50) | (7.93) |
Working Capital |
2.15 | 1.48 | (1.57) | (6.66) | (0.82) | (4.16) | (1.04) | 3.14 | 2.67 |
Capital Expenditures |
— | — | — | — | — | — | — | — | (0.12) |
Net Current Asset Value |
(195.12) | (197.92) | (190.31) | (6.66) | (8.91) | (4.62) | (1.07) | 3.13 | 2.67 |
EV/EBIT |
— | — | — | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.11 |
Capex to Sales |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | — | — | 1.00 | 0.00 | — | 0.00 | 0.00 | 0.05 |
Cash ROIC |
(3.55%) | (18.60%) | (21.50%) | 24.93% | (96.43%) | 2,411.03% | (2,282.45%) | (109.02%) | (110.21%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 12.17 | 7.02 | 11.92 | 47.00 | 18.61 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — | — |
Average Receivables |
— | 0.15 | 0.15 | — | 0.29 | 0.36 | 0.19 | 0.11 | 0.27 |
Average Payables |
0.27 | 0.27 | 1.60 | 2.25 | 1.01 | 1.62 | 2.44 | 1.65 | 2.31 |
Average Assets |
203.63 | 203.63 | 200.67 | 98.43 | 8.38 | 11.15 | 4.30 | 4.15 | 6.52 |
Average Common Equity |
5.00 | 5.00 | 5.00 | (0.83) | (7.41) | (6.09) | (2.34) | 1.36 | 3.13 |
Columns are period end dates